Beiersdorf Aktiengesellschaft (ETR:BEI)
| Market Cap | 15.89B -40.4% |
| Revenue (ttm) | 9.85B +0.0% |
| Net Income | 939.00M +3.0% |
| EPS | 4.25 +4.8% |
| Shares Out | 218.52M |
| PE Ratio | 17.12 |
| Forward PE | 16.64 |
| Dividend | 1.00 (1.38%) |
| Ex-Dividend Date | Apr 24, 2026 |
| Volume | n/a |
| Average Volume | 385,388 |
| Open | 72.82 |
| Previous Close | 72.74 |
| Day's Range | 72.60 - 73.46 |
| 52-Week Range | 69.10 - 122.60 |
| Beta | 0.49 |
| RSI | 49.88 |
| Earnings Date | Aug 5, 2026 |
About ETR:BEI
Beiersdorf Aktiengesellschaft, together with its subsidiaries, manufactures and distributes consumer goods in Europe, the United States, Africa, Asia, and Australia. The company operates through two segments: Consumer Business and Tesa Business. The Consumer Business Segment offers skin and body care products. The Tesa Business segment provides adhesive tapes and self-adhesive solutions for industries, craft businesses, and consumers. This segment also offers its system solutions to the automotive, consumer electronics, printing and packaging, ... [Read more]
Financial Performance
In 2025, ETR:BEI's revenue was 9.85 billion, an increase of 0.02% compared to the previous year's 9.85 billion. Earnings were 939.00 million, an increase of 2.96%.
Financial StatementsNews
MMJ International Holdings: CMS Hemp Program Insiders Admit Bypassing FDA Safety Standards for a Potential $34.5 Billion Medicare Payday
BEI Participants Publicly Discuss "Bypassing" FDA Pathway as Federal Court Weighs Legality of CMS Cannabinoid ProgramOn-Camera Statements From CMS Cannabinoid Program Participants Raise New Questio...
EQS-CMS: Beiersdorf Aktiengesellschaft: Announcement pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) no 596/2014 and Art. 2 para. 2 and 3 of Delegated Regulation (EU) no. 2016/1052
EQS Post-admission Duties announcement: Beiersdorf Aktiengesellschaft / Share Buyback Program 2026/2027 – Interim Report 1 Beiersdorf Aktiengesellschaft: Announcement pursuant to Art. 5 para. 1 lit. b...
EQS-CMS: Beiersdorf Aktiengesellschaft: Release of a capital market information
EQS Post-admission Duties announcement: Beiersdorf Aktiengesellschaft / Announcement pursuant to Article 5 para. 1 lit. a) of Regulation (EU) No. 596/2014 and Article 2 para. 1 of the Delegated Regula...
Beiersdorf Aktiengesellschaft Transcript: AGM 2026
The AGM highlighted solid financial results amid a challenging market, with strategic focus on NIVEA's repositioning, innovation, and expansion in key markets. Shareholders approved all proposals, including a EUR 1 dividend and share buyback, while management addressed concerns on growth, acquisitions, and remuneration.
Beiersdorf Aktiengesellschaft Transcript: AGM 2026
The AGM highlighted solid financial results amid a challenging market, with strategic focus on NIVEA's repositioning, innovation, and expansion in key markets. Shareholders approved all proposals, including a EUR 1 dividend and share buyback, while management addressed concerns on growth, acquisitions, and remuneration.
Beiersdorf Aktiengesellschaft Transcript: AGM 2026
The AGM highlighted solid financial results amid a challenging market, with strategic focus on NIVEA's repositioning, innovation, and expansion in key markets. Shareholders approved all proposals, including a EUR 1 dividend and share buyback, while management addressed concerns on growth, acquisitions, and remuneration.
Beiersdorf Aktiengesellschaft Transcript: AGM 2026
The AGM highlighted solid financial results amid a challenging market, with strategic focus on NIVEA's repositioning, innovation, and expansion in key markets. Shareholders approved all proposals, including a EUR 1 dividend and share buyback, while management addressed concerns on growth, acquisitions, and remuneration.
Beiersdorf AG (BDRFF) Q1 2026 Earnings Call Highlights: Navigating Sales Declines and Strategic ...
Beiersdorf AG (BDRFF) Q1 2026 Earnings Call Highlights: Navigating Sales Declines and Strategic Growth
Beiersdorf Aktiengesellschaft Earnings Call Transcript: Q1 2026
Q1 2026 saw a 4.6% organic net sales decline, with Derma delivering strong growth and Nivea and La Prairie facing headwinds. Early signs of improved sell-out and ongoing strategic rebalancing support a cautiously optimistic outlook for the year.
Beiersdorf Aktiengesellschaft Earnings release: Q1 2026
Beiersdorf Aktiengesellschaft released its Q1 2026 earnings on April 21, 2026, summarizing the period's financial results.
Beiersdorf Aktiengesellschaft Slides: Q1 2026
Beiersdorf Aktiengesellschaft has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 21, 2026.
Beiersdorf Aktiengesellschaft Earnings Call Transcript: Q1 2026
Q1 2026 saw a 4.6% organic net sales decline, with Derma delivering strong growth and Nivea and La Prairie facing headwinds. Early signs of improved sell-out and ongoing strategic rebalancing support a cautiously optimistic outlook for the year.
Beiersdorf Aktiengesellschaft Earnings release: Q1 2026
Beiersdorf Aktiengesellschaft released its Q1 2026 earnings on April 21, 2026, summarizing the period's financial results.
Beiersdorf Aktiengesellschaft Slides: Q1 2026
Beiersdorf Aktiengesellschaft has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 21, 2026.
Beiersdorf Aktiengesellschaft Earnings Call Transcript: Q1 2026
Q1 2026 saw a 4.6% organic net sales decline, with Derma delivering strong growth and Nivea and La Prairie facing headwinds. Early signs of improved sell-out and ongoing strategic rebalancing support a cautiously optimistic outlook for the year.
Beiersdorf Aktiengesellschaft Earnings release: Q1 2026
Beiersdorf Aktiengesellschaft released its Q1 2026 earnings on April 21, 2026, summarizing the period's financial results.
Beiersdorf Aktiengesellschaft Slides: Q1 2026
Beiersdorf Aktiengesellschaft has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 21, 2026.
Beiersdorf Aktiengesellschaft Earnings Call Transcript: Q1 2026
Q1 2026 saw a 4.6% organic net sales decline, with Derma delivering strong growth and Nivea and La Prairie facing headwinds. Early signs of improved sell-out and ongoing strategic rebalancing support a cautiously optimistic outlook for the year.
Beiersdorf Aktiengesellschaft Earnings release: Q1 2026
Beiersdorf Aktiengesellschaft released its Q1 2026 earnings on April 21, 2026, summarizing the period's financial results.
Beiersdorf Aktiengesellschaft Slides: Q1 2026
Beiersdorf Aktiengesellschaft has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 21, 2026.
Is Beiersdorf stock a buy after 44% crash? UBS upgrade offers key signals
Beiersdorf stock's long slump has finally been enough to make one major broker step back from its bearish stance. UBS upgraded the German skincare and consumer-goods group to “neutral” from “sell” on ...
Beiersdorf Shares Fall on Sluggish 2026 Outlook
The cosmetics company expects slow sales this year, particularly in its consumer business segment.
Beiersdorf Aktiengesellschaft Earnings Call Transcript: Q4 2025
Despite a challenging year marked by market slowdowns and cost pressures, the group delivered modest sales and profit growth, driven by strong Derma performance and innovation. Strategic repositioning of NIVEA and continued investment in R&D and shareholder returns are key priorities.
Beiersdorf Aktiengesellschaft Annual report: Q4 2025
Beiersdorf Aktiengesellschaft has published its Q4 2025 annual report on March 3, 2026.
Beiersdorf Aktiengesellschaft Earnings release: Q4 2025
Beiersdorf Aktiengesellschaft released its Q4 2025 earnings on March 3, 2026, summarizing the period's financial results.